Domino Introduces Fast-Drying Ink for High-Speed Coding - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Domino Introduces Fast-Drying Ink for High-Speed Coding
The new ink takes less a second to dry and is four times more fade resistant than inks that are typically used in retail packaging.



Domino Printing Sciences, announced that it has launched a new ultra-fast-drying ink for companies that require "item level serialization whilst maintaining line speeds.” The new ink (BK652) takes less than one second to dry and is four times more resistance to fading than typical inks used in retail packaging, stated Domino in its press release.

The ink was developed in response to the EU Falsified Medicines Directive (FMD) according to Domino's life sciences manager, Craig Stobie. "Under the legislation pharmaceutical product will be authenticated at the point of dispensation, making long term ink lightfastness and contrast vitally important, even after what could be years in the supply chain."

Alan Mutch, product manager for thermal ink jet at Domino, said that this product was “reformulated in light of the legislative requirements in Europe and US.” Designed for use with Domino’s G-Series thermal ink jets, the ink can print high-definition coding onto various substrates such as cartons, sachets, pouches, labels and blister packs.

The rapid drying means that data and codes can be fixed and bonded without delaying packaging productivity. Operational efficiency can be increased as cartons with data printed using BK652 can be picked up in the second and third operations on the packaging line much quicker. The ink also cuts de-cap time and thereby reduces initial rejects that manufacturers tend to see after the machine has been left idle.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
24%
Oversee medical treatment of patients in the US.
12%
Provide treatment for patients globally.
10%
All of the above.
44%
No government involvement in patient treatment or drug development.
10%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?

Click here